Vishwanath Venketaraman

Prof. Vishwanath Venketaraman

Western University of Health and Sciences College of Osteopathic Medicine of the Pacific, Pomona, California, USA
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KTKimberly To
Kimberly To
RCRuoqiong Cao
Ruoqiong Cao
AYAram Yegiazaryan
Aram Yegiazaryan
JOjames owens
james owens
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
Nontuberculous mycobacteria (NTM) are emerging human pathogens, causing a wide range of clinical diseases affecting individuals who are immunocompromised and who have underlying health conditions. NTM are ubiquitous in the environment, with certain species causing opportunistic infection in humans, including Mycobacterium avium and Mycobacterium abscessus. The incidence and prevalence of NTM infections are rising globally, especially in developed countries with declining incidence rates of M. tuberculosis infection. Mycobacterium avium, a slow-growing mycobacterium, is associated with Mycobacterium avium complex (MAC) infections that can cause chronic pulmonary disease, disseminated disease, as well as lymphadenitis. M. abscessus infections are considered one of the most antibiotic-resistant mycobacteria and are associated with pulmonary disease, especially cystic fibrosis, as well as contaminated traumatic skin wounds, postsurgical soft tissue infections, and healthcare-associated infections (HAI). Clinical manifestations of diseases depend on the interaction of the host’s immune response and the specific mycobacterial species. This review will give a general overview of the general characteristics, vulnerable populations most at risk, pathogenesis, treatment, and prevention for infections caused by Mycobacterium avium, in the context of MAC, and M. abscessus.

21 October 2021 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
SSShayan Shiehzadegan
Shayan Shiehzadegan
NANazanin Alaghemand
Nazanin Alaghemand
MFMichael Steven Fox
Michael Steven Fox
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
With the delta variant of COVID-19, known as B.1.617.2, quickly ramping up infections around the world, we need to understand what makes this variant more contagious. One study has reported that the delta variant is 60% more transmissible than the alpha variant. As of August 2021, the delta variant has quickly become the dominant strain. Despite countries like the US, where most of the population is vaccinated, COVID-19 has made a resurgence in infections. Collectively, as a country, we ask: is it more deadly? What makes it more “contagious” or “transmissible”? This review article delves into the information we already know about the delta variant and how it compares with the other SARS-CoV-2 variants. The current vaccine companies like AstraZeneca, Pfizer/BioNTech, and Moderna have reported that their vaccines can provide protection against this variant but with a slightly reduced efficacy. In this article, we do a comprehensive review and summary of the delta B.1.617.2 variant and what makes it more contagious.

Verified
Journal Article
Open access
PDF file
WZWeixia Zhong
Weixia Zhong
OSOmar Shahbaz
Omar Shahbaz
GTGarrett Teskey
Garrett Teskey
ABAbrianna Beever
Abrianna Beever
NKNala Kachour
Nala Kachour
NDNissar Darmani
Nissar Darmani
Nausea and vomiting are common gastrointestinal complaints that can be triggered by diverse emetic stimuli through central and/or peripheral nervous systems. Both nausea and vomiting are considered as defense mechanisms when threatening toxins/drugs/bacteria/viruses/fungi enter the body either via the enteral (e.g., the gastrointestinal tract) or parenteral routes, including the blood, skin, and respiratory systems. While vomiting is the act of forceful removal of gastrointestinal contents, nausea is believed to be a subjective sensation that is more difficult to study in nonhuman species. In this review, the authors discuss the anatomical structures, neurotransmitters/mediators, and corresponding receptors, as well as intracellular emetic signaling pathways involved in the processes of nausea and vomiting in diverse animal models as well as humans. While blockade of emetic receptors in the prevention of vomiting is fairly well understood, the potential of new classes of antiemetics altering postreceptor signal transduction mechanisms is currently evolving, which is also reviewed. Finally, future directions within the field will be discussed in terms of important questions that remain to be resolved and advances in technology that may help provide potential answers.

29 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
John DawiJohn Dawi
John Dawi
KTKevin Tumanyan
Kevin Tumanyan
KTKirakos Tomas
Kirakos Tomas
YMYura Misakyan
Yura Misakyan
AGAreg Gargaloyan
Areg Gargaloyan
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
Diabetic foot ulcers (DFUs) are among the most common and debilitating complications of diabetes mellitus (DM), affecting approximately 15–25% of patients and contributing to over 85% of non-traumatic amputations. DFUs impose a substantial clinical and economic burden due to high recurrence rates, prolonged wound care, and frequent hospitalizations, accounting for billions in healthcare costs worldwide. The multifactorial pathophysiology of DFUs involves peripheral neuropathy, peripheral arterial disease, chronic inflammation, and impaired tissue regeneration. Recent studies underscore the importance of immune dysregulation—specifically macrophage polarization imbalance, regulatory T cell dysfunction, and neutrophil impairment—as central mechanisms in wound chronicity. These immune disruptions sustain a pro-inflammatory environment dominated by cytokines, such as TNF-α, IL-1β, and IL-6, which impair angiogenesis and delay repair. This review provides an updated synthesis of DFU pathogenesis, emphasizing immune dysfunction and its therapeutic implications. We examine emerging strategies in immunomodulation, regenerative medicine, and AI-based wound technologies, including SGLT2 inhibitors, biologics, stem cell therapies, and smart dressing systems. These approaches hold promise for accelerating healing, reducing amputation risk, and personalizing future DFU care.

1 March 1998 in Cell Death & Differentiation
Verified
Journal Article
Closed access
Francesco Di VirgilioFrancesco Di Virgilio
Francesco Di Virgilio
PCPaola Chiozzi
Paola Chiozzi
SFSimonetta Falzoni
Simonetta Falzoni
DFDAVIDE FERRARI
DAVIDE FERRARI
JSJuana M Sanz
Juana M Sanz
OBOlavio R Baricordi
Olavio R Baricordi

1 January 2018
Verified
Book Chapter
Closed access
GTGarrett Teskey
Garrett Teskey
RARachel Abrahem
Rachel Abrahem
RCRuoqiong Cao
Ruoqiong Cao
KGKaro Gyurjian
Karo Gyurjian
HIHicret Islamoglu
Hicret Islamoglu
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman